Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 183


The prognostic value of ribonucleotide reductase small subunit M2 in predicting recurrence for prostate cancers.

Huang Y, Liu X, Wang YH, Yeh SD, Chen CL, Nelson RA, Chu P, Wilson T, Yen Y.

Urol Oncol. 2014 Jan;32(1):51.e9-19. doi: 10.1016/j.urolonc.2013.08.002.


Ribonucleotide reductase M2 subunit expression and prognostic value in nasopharyngeal carcinoma.

Han P, Lin ZR, Xu LH, Zhong Q, Zhu XF, Liang FY, Cai Q, Huang XM, Zeng MS.

Mol Med Rep. 2015 Jul;12(1):401-9. doi: 10.3892/mmr.2015.3360. Epub 2015 Feb 16.


Excision repair cross-complementing gene-1, ribonucleotide reductase subunit M1, ribonucleotide reductase subunit M2, and human equilibrative nucleoside transporter-1 expression and prognostic value in biliary tract malignancy.

Fisher SB, Fisher KE, Patel SH, Lim MG, Kooby DA, El-Rayes BF, Staley CA 3rd, Adsay NV, Farris AB 3rd, Maithel SK.

Cancer. 2013 Jan 15;119(2):454-62. doi: 10.1002/cncr.27739. Epub 2012 Jul 3.


Ribonucleotide reductase M2 does not predict survival in patients with resectable pancreatic adenocarcinoma.

Xie H, Lin J, Thomas DG, Jiang W, Liu X.

Int J Clin Exp Pathol. 2012;5(4):347-55. Epub 2012 Apr 16.


Ribonucleotide reductase small subunit M2 serves as a prognostic biomarker and predicts poor survival of colorectal cancers.

Liu X, Zhang H, Lai L, Wang X, Loera S, Xue L, He H, Zhang K, Hu S, Huang Y, Nelson RA, Zhou B, Zhou L, Chu P, Zhang S, Zheng S, Yen Y.

Clin Sci (Lond). 2013 May;124(9):567-78. doi: 10.1042/CS20120240.


XPA-210: a new proliferation marker determines locally advanced prostate cancer and is a predictor of biochemical recurrence.

Aufderklamm S, Hennenlotter J, Todenhoefer T, Gakis G, Schilling D, Vogel U, Kuehs U, Dlugosch J, Knapp J, Merseburger A, Gerber V, Ordelheide A, Hevler J, Stenzl A, Schwentner C.

World J Urol. 2012 Aug;30(4):547-52. doi: 10.1007/s00345-011-0768-y. Epub 2011 Oct 4.


Upregulation of RASGRP3 expression in prostate cancer correlates with aggressive capabilities and predicts biochemical recurrence after radical prostatectomy.

Zeng X, Hu Z, Wang Z, Tao J, Lu T, Yang C, Lee B, Ye Z.

Prostate Cancer Prostatic Dis. 2014 Jun;17(2):119-25. doi: 10.1038/pcan.2013.51. Epub 2014 Jan 14.


Overexpression of catalytic subunit M2 in patients with ovarian cancer.

Wang LM, Lu FF, Zhang SY, Yao RY, Xing XM, Wei ZM.

Chin Med J (Engl). 2012 Jun;125(12):2151-6.


Prognostic and therapeutic significance of ribonucleotide reductase small subunit M2 in estrogen-negative breast cancers.

Zhang H, Liu X, Warden CD, Huang Y, Loera S, Xue L, Zhang S, Chu P, Zheng S, Yen Y.

BMC Cancer. 2014 Sep 11;14:664. doi: 10.1186/1471-2407-14-664.


Presence or absence of a positive pathological margin outperforms any other margin-associated variable in predicting clinically relevant biochemical recurrence in Gleason 7 prostate cancer.

Huang JG, Pedersen J, Hong MK, Harewood LM, Peters J, Costello AJ, Hovens CM, Corcoran NM.

BJU Int. 2013 May;111(6):921-7. doi: 10.1111/j.1464-410X.2012.11665.x. Epub 2013 Jan 25.


Overexpressed Rce1 is positively correlated with tumor progression and predicts poor prognosis in prostate cancer.

Huang L, Li M, Wang D, He J, Wu W, Zeng Q, Li J, Xiao M, Hu J, He Y, Li Y, Mai L, Liu W.

Hum Pathol. 2016 Jan;47(1):109-14. doi: 10.1016/j.humpath.2015.08.021. Epub 2015 Sep 28.


Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer.

Song C, Kang T, Yoo S, Jeong IG, Ro JY, Hong JH, Kim CS, Ahn H.

Urol Oncol. 2013 Feb;31(2):168-74. doi: 10.1016/j.urolonc.2010.11.005. Epub 2011 Jun 29.


The expression of ribonucleotide reductase M2 in the carcinogenesis of uterine cervix and its relationship with clinicopathological characteristics and prognosis of cancer patients.

Su YF, Wu TF, Ko JL, Tsai HT, Tee YT, Chien MH, Chou CH, Lin WL, Low HY, Chou MY, Yang SF, Wang PH.

PLoS One. 2014 Mar 17;9(3):e91644. doi: 10.1371/journal.pone.0091644. eCollection 2014.


High expression of ribonucleotide reductase subunit M2 correlates with poor prognosis of hepatocellular carcinoma.

Lee B, Ha SY, Song DH, Lee HW, Cho SY, Park CK.

Gut Liver. 2014 Nov;8(6):662-8. doi: 10.5009/gnl13392. Epub 2014 Nov 15.


E2F1 promote the aggressiveness of human colorectal cancer by activating the ribonucleotide reductase small subunit M2.

Fang Z, Gong C, Liu H, Zhang X, Mei L, Song M, Qiu L, Luo S, Zhu Z, Zhang R, Gu H, Chen X.

Biochem Biophys Res Commun. 2015 Aug 21;464(2):407-15. doi: 10.1016/j.bbrc.2015.06.103. Epub 2015 Jun 18.


Expression status of ribonucleotide reductase small subunits hRRM2/p53R2 as prognostic biomarkers in stage I and II non-small cell lung cancer.

Hsu NY, Wu JY, Liu X, Yen Y, Chen CY, Chou MC, Lin CH, Lee H, Cheng YW.

Anticancer Res. 2011 Oct;31(10):3475-81.


Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.

Ploussard G, Agamy MA, Alenda O, Allory Y, Mouracade P, Vordos D, Hoznek A, Abbou CC, de la Taille A, Salomon L.

BJU Int. 2011 Jun;107(11):1748-54. doi: 10.1111/j.1464-410X.2010.09728.x. Epub 2010 Sep 30.


Expression of ribonucleotide reductase M2 subunit in gastric cancer and effects of RRM2 inhibition in vitro.

Morikawa T, Hino R, Uozaki H, Maeda D, Ushiku T, Shinozaki A, Sakatani T, Fukayama M.

Hum Pathol. 2010 Dec;41(12):1742-8. doi: 10.1016/j.humpath.2010.06.001. Epub 2010 Sep 9.


Supplemental Content

Support Center